Literature DB >> 15802099

Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome.

Fathia Gibril1, Robert T Jensen.   

Abstract

Gastrinomas producing Zollinger-Ellison syndrome are the most frequent symptomatic, malignant pancreatic endocrine tumor syndrome. Recently, a number of important studies have examined their molecular pathogenesis and natural history and provided important guidelines for their treatment. Each of these areas is briefly reviewed in this article.

Entities:  

Mesh：

Year:  2005        PMID： 15802099     DOI： 10.1007/s11894-005-0049-2

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN： 1522-8037


  59 in total

1.  Management of islet cell tumors in patients with multiple endocrine neoplasia: a prospective study.

Authors:  B C Sheppard; J A Norton; J L Doppman; P N Maton; J D Gardner; R T Jensen
Journal:  Surgery       Date:  1989-12       Impact factor: 3.982

2.  Surgical resection of intracardiac gastrinoma.

Authors:  S Noda; J A Norton; R T Jensen; W A Gay
Journal:  Ann Thorac Surg       Date:  1999-02       Impact factor: 4.330

3.  Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome.

Authors:  J A Norton; H R Alexander; D L Fraker; D J Venzon; F Gibril; R T Jensen
Journal:  Ann Surg       Date:  2001-10       Impact factor: 12.969

4.  Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy.

Authors:  R Lebtahi; G Cadiot; N Delahaye; R Genin; D Daou; M C Peker; D Chosidow; M Faraggi; M Mignon; D Le Guludec
Journal:  J Nucl Med       Date:  1999-10       Impact factor: 10.057

Review 5.  Somatostatin receptor imaging.

Authors:  Dik J Kwekkeboom; Eric P Krenning
Journal:  Semin Nucl Med       Date:  2002-04       Impact factor: 4.446

6.  Loss of heterozygosity of chromosome 1q in gastrinomas: occurrence and prognostic significance.

Authors:  Yuan-Jia Chen; Alexander Vortmeyer; Zhengping Zhuang; Steve Huang; Robert T Jensen
Journal:  Cancer Res       Date:  2003-02-15       Impact factor: 12.701

Review 7.  Peptide receptor imaging and therapy.

Authors:  D Kwekkeboom; E P Krenning; M de Jong
Journal:  J Nucl Med       Date:  2000-10       Impact factor: 10.057

Review 8.  Hepatic surgery for metastases from neuroendocrine tumors.

Authors:  Juan M Sarmiento; Florencia G Que
Journal:  Surg Oncol Clin N Am       Date:  2003-01       Impact factor: 3.495

9.  Possible primary lymph node gastrinoma: occurrence, natural history, and predictive factors: a prospective study.

Authors:  Jeffrey A Norton; H Richard Alexander; Douglas L Fraker; David J Venzon; Fathia Gibril; Robert T Jensen
Journal:  Ann Surg       Date:  2003-05       Impact factor: 12.969

Review 10.  Apparent lymph node primary gastrinoma.

Authors:  W S Arnold; D L Fraker; H R Alexander; H C Weber; J A Norton; R T Jensen
Journal:  Surgery       Date:  1994-12       Impact factor: 3.982
View more
  17 in total

1.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.

Authors:  Matthew H Kulke; Lowell B Anthony; David L Bushnell; Wouter W de Herder; Stanley J Goldsmith; David S Klimstra; Stephen J Marx; Janice L Pasieka; Rodney F Pommier; James C Yao; Robert T Jensen
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

2.  Primary hepatic gastrinoma: an unusual case of zollinger-ellison syndrome.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-01

Review 3.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 4.  Diagnosis of Zollinger-Ellison syndrome: increasingly difficult.

Authors:  Tetsuhide Ito; Guillaume Cadiot; Robert T Jensen
Journal:  World J Gastroenterol       Date:  2012-10-21       Impact factor: 5.742

Review 5.  Zollinger-Ellison syndrome: classical considerations and current controversies.

Authors:  Irene Epelboym; Haggi Mazeh
Journal:  Oncologist       Date:  2013-12-06

6.  Neuroendocrine tumors of the small bowels are on the rise: Early aspects and management.

Authors:  Hans Scherübl; Robert T Jensen; Guillaume Cadiot; Ulrich Stölzel; Günter Klöppel
Journal:  World J Gastrointest Endosc       Date:  2010-10-16

7.  Rare diseases in clinical endocrinology: a taxonomic classification system.

Authors:  G Marcucci; L Cianferotti; P Beck-Peccoz; M Capezzone; F Cetani; A Colao; M V Davì; E degli Uberti; S Del Prato; R Elisei; A Faggiano; D Ferone; C Foresta; L Fugazzola; E Ghigo; G Giacchetti; F Giorgino; A Lenzi; P Malandrino; M Mannelli; C Marcocci; L Masi; F Pacini; G Opocher; A Radicioni; M Tonacchera; R Vigneri; M C Zatelli; M L Brandi
Journal:  J Endocrinol Invest       Date:  2014-11-07       Impact factor: 4.256

Review 8.  Zollinger-Ellison syndrome: recent advances and controversies.

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  Curr Opin Gastroenterol       Date:  2013-11       Impact factor: 3.287

Review 9.  Pharmacotherapy of Zollinger-Ellison syndrome.

Authors:  Tetsuhide Ito; Hisato Igarashi; Hirotsugu Uehara; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2013-01-30       Impact factor: 3.889

Review 10.  Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.

Authors:  Marc J Berna; Robert T Jensen
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.